Literature DB >> 30949913

JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).

Shinsuke Iida1, Tadao Ishida2, Hirokazu Murakami3, Shuji Ozaki4, Masahiro Abe5, Hiroyuki Hata6, Chihiro Shimazaki7.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30949913     DOI： 10.1007/s12185-019-02636-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  4 in total

1.  Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.

Authors:  Kenshi Suzuki; Noriko Doki; Kuniaki Meguro; Kazutaka Sunami; Hiroshi Kosugi; Osamu Sasaki; Toshiyuki Takagi; Hirokazu Murakami; Kazuyuki Shimizu
Journal:  Int J Hematol       Date:  2019-07-19       Impact factor: 2.490

2.  Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.

Authors:  Yoshihide Kakimoto; Miyako Hoshino; Mikiko Hashimoto; Masaya Hiraizumi; Kohei Shimizu; Takaaki Chou
Journal:  Intern Med       Date:  2021-10-12       Impact factor: 1.282

3.  Multiple myeloma with onset of pancreas involvement: A case report.

Authors:  Xin Wang; Huaiya Xie; Lu Zhang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 4.  Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.

Authors:  Tomotaka Suzuki; Dai Maruyama; Shinsuke Iida; Hirokazu Nagai
Journal:  Jpn J Clin Oncol       Date:  2022-09-18       Impact factor: 2.925
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.